Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 367 participants.
Also called NCT06415773
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 367 participants
- Registry
-
NCT06415773
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06415773. Randomized; double masking; primary purpose treatment. Start 2024-06-04 (actual); primary completion 2025-06-13 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
- Acronym
- HARMONY
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Intervention (Drug)
- HTD1801
- Intervention (Drug)
- Dapagliflozin
- Lead sponsor
- Shenzhen HighTide Biopharmaceutical Ltd.
Record details
- Record id
cardio:ct-nct06415773- Content hash
b5a4b985f7df987f4408731c9f5b34ef416d10fdaeaf38d659517df80eb22032